专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明专利

CA3098335A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF 未知
公开(公告)号：CA3098335A1
公开(公告)日：2019-10-31
申请号：CA3098335
申请日：2019-04-23
申请人： MERCK PATENT GMBH , VERTEX PHARMA
发明人： YU HENRY , CLARK MICHAEL , BEMIS GUY , BOYD MICHAEL , CHANDUPATLA KISHAN , COLLIER PHILIP , DENG HONGBO , DONG HUIJUN , DORSCH WARREN , HOOVER RUSSELL R , JOHNSON MAC ARTHUR , KUKAMI SHASHANK , PENNEY MARINA , RONKIN STEVEN , TAKEMOTO DARIN , TANG QING , WAAL NATHAN D , WANG TIANSHENG , LAUFFER DAVID J , LI PAN
IPC分类号： C07D413/14 , A61K31/553 , A61P35/00 , C07D403/04 , C07D409/14 , C07D413/04
摘要： The present invention provides compounds of Formula (I'), or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g. cancer).

12. 发明申请

WO2012024363A3 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS 审中-公开
标题翻译：用于治疗或预防黄疸病毒感染的化合物和方法
公开(公告)号：WO2012024363A3
公开(公告)日：2012-05-31
申请号：PCT/US2011048027
申请日：2011-08-17
申请人： VERTEX PHARMA , GREEN JEREMY , KONG LAVAL CHAN CHUN , DAS SANJOY KUMAR , POISSON CARL , NANTHAKUMAR SUGANTHINI , WAAL NATHAN , LI PAN , RONKIN STEVEN , LAUFFER DAVID J , WILSON DEAN M
发明人： GREEN JEREMY , KONG LAVAL CHAN CHUN , DAS SANJOY KUMAR , POISSON CARL , NANTHAKUMAR SUGANTHINI , WAAL NATHAN , LI PAN , RONKIN STEVEN , LAUFFER DAVID J , WILSON DEAN M
IPC分类号： C07D333/38 , A61K31/381 , A61P31/12 , C07D333/40 , C07D409/06 , C07D409/12 , C07D413/12 , C07D417/12
CPC分类号： A61K31/427 , A61K31/381 , A61K31/422 , A61K31/4245 , A61K31/4436 , A61K31/4535 , A61K31/497 , A61K31/5377 , A61K31/7056 , A61K38/212 , C07D333/38 , C07D333/40 , C07D409/06 , C07D409/12 , C07D413/12 , C07D417/12
摘要： A compound is selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof.
摘要翻译：化合物选自图1中所示的结构式。 1或其药学上可接受的盐。药物组合物包含选自图1中描绘的结构式的化合物。 1或其药学上可接受的盐和赋形剂的药学上可接受的载体。治疗受试者的HCV感染的方法包括向受试者施用治疗有效量的选自图1中描述的结构式的治疗有效量的化合物。 1或其药学上可接受的盐。抑制或降低受试者中或生物体外样品中HCV聚合酶活性的方法包括向受试者或样品施用治疗有效量的选自图1中描述的结构式的治疗有效量。 1或其药学上可接受的盐。

13. 发明申请

WO2009045992A2 C-MET PROTEIN KINASE INHIBITORS 审中-公开
标题翻译： C-MET蛋白激酶抑制剂
公开(公告)号：WO2009045992A2
公开(公告)日：2009-04-09
申请号：PCT/US2008078239
申请日：2008-09-30
申请人： VERTEX PHARMA , LAUFFER DAVID , LI PAN , WAAL NATHAN , MCGINTY KIRA , TANG QING , RONKIN STEVEN , FARMER LUC , SHANNON DEAN , JACOBS DYLAN
发明人： LAUFFER DAVID , LI PAN , WAAL NATHAN , MCGINTY KIRA , TANG QING , RONKIN STEVEN , FARMER LUC , SHANNON DEAN , JACOBS DYLAN
IPC分类号： A61K31/4439
CPC分类号： C07D401/14 , C07D409/14 , C07D417/14
摘要： The present invention relates to compounds of formula I useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative disorders. Formula (I).
摘要翻译：本发明涉及用于抑制c-Met蛋白激酶的式I化合物。本发明还提供了包含本发明化合物的药学上可接受的组合物以及使用该组合物治疗增殖性疾病的方法。公式（I）。

14. 发明专利

AU2019261308B2 Antiproliferation compounds and uses thereof 未知
公开(公告)号：AU2019261308B2
公开(公告)日：2022-09-08
申请号：AU2019261308
申请日：2019-04-23
申请人： MERCK PATENT GMBH , VERTEX PHARMACEUTICALS INCORPORATED
发明人： YU HENRY , CLARK MICHAEL , BEMIS GUY , BOYD MICHAEL , CHANDUPATLA KISHAN , COLLIER PHILIP , DENG HONGBO , DONG HUIJUN , DORSCH WARREN , HOOVER RUSSELL R , JOHNSON JR MAC ARTHUR , KUKAMI SHASHANK , PENNEY MARINA , RONKIN STEVEN , TAKEMOTO DARIN , TANG QING , WAAL NATHAN D , WANG TIANSHENG , LAUFFER DAVID J , LI PAN
IPC分类号： C07D413/14 , A61K31/553 , A61P35/00 , C07D403/04 , C07D409/14 , C07D413/04
摘要： The present invention provides compounds of Formula (I'), or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g. cancer).

15. 发明专利

HUE057527T2 DNS-PK inhibitorok 未知
公开(公告)号：HUE057527T2
公开(公告)日：2022-05-28
申请号：HUE18207382
申请日：2014-03-12
申请人： VERTEX PHARMA
发明人： MAXWELL JOHN , CHARIFSON PAUL , TANG QING , RONKIN STEVEN , JACKSON KATRINA , PIERCE ALBERT , LAUFFER DAVID , LI PAN , GIROUX SIMON , XU JINWANG , MORRIS MARK , COURT JOHN , COTTRELL KEVIN , DENG HONGBO , WAAL NATHAN , GU WENXIN
IPC分类号： C07D403/12 , A61P35/00 , C07D241/44 , C07D405/12 , C07D413/04 , C07D417/12

16. 发明专利

NZ592569A C-MET PROTEIN KINASE INHIBITORS 未知
公开(公告)号：NZ592569A
公开(公告)日：2012-05-25
申请号：NZ59256909
申请日：2009-10-20
申请人： VERTEX PHARMA
发明人： LAUFFER DAVID , LI PAN , MCGINTY KIRA , RONKIN STEVEN , TANG QING , GRILLOT ANNE-LAURE , WAAL NATHAN
IPC分类号： C07D401/04 , C07D401/14 , C07D405/14 , C07D409/14 , C07D451/06
摘要： Disclosed are tetrazole piperazine compounds represented by general formula (I), or pharmaceutically acceptable salts thereof, wherein RA is a phenyl or 5-9 membered heteroaryl. The compounds are used to treat a proliferative disorder such as cancer.

17. 发明专利

CA2808291A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS 未知
公开(公告)号：CA2808291A1
公开(公告)日：2012-02-23
申请号：CA2808291
申请日：2011-08-17
申请人： VERTEX PHARMA
发明人： GREEN JEREMY , NANTHAKUMAR SUGANTHINI , WAAL NATHAN , LI PAN , RONKIN STEVEN , LAUFFER DAVID J , WILSON DEAN M , DAS SANJOY KUMAR , KONG LAVAL CHAN CHUN , POISSON CARL
IPC分类号： C07D333/38 , A61K31/381 , A61P31/12 , C07D333/40 , C07D409/06 , C07D409/12 , C07D413/12 , C07D417/12
摘要： A compound is selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof.

18. 发明专利

AT433980T 未知
公开(公告)号：AT433980T
公开(公告)日：2009-07-15
申请号：AT04810009
申请日：2004-10-21
申请人： VERTEX PHARMA
发明人： CHARIFSON PAUL , DEININGER DAVID , GRILLOT ANNE-LAURE , LIAO YUSHENG , RONKIN STEVEN , STAMOS DEAN , PEROLA EMANUELE , WANG TIANSHENG , LE TIRAN ARNAUD , DRUMM JOSEPH
IPC分类号： C07D491/04 , A61K31/4184 , A61K31/4439 , A61K31/506 , A61P31/00 , A61P31/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04
摘要： The present invention relates to compounds that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.

19. 发明专利

BG64507B1 CARBAMIDE DERIVATIVES AS INHIBITORS OF ENZYME INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE 未知
公开(公告)号：BG64507B1
公开(公告)日：2005-05-31
申请号：BG10294598
申请日：1998-11-23
申请人： VERTEX PHARMA
发明人： ARMISTEAD DAVID , BADIA MICHAEL , BEMIS GUY , BETHIEL RANDY , FRANK CATHARINE , NOVAK PERRY , RONKIN STEVEN , SAUNDERS JEFFREY
IPC分类号： A61K31/17 , A61K31/18 , A61K31/404 , A61K31/42 , A61K31/421 , A61K31/422 , A61P9/14 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/06 , A61P43/00 , C07C275/42 , C07D263/18 , C07D263/32 , C07D277/18 , C07D413/12 , C07C275/28 , C07C275/34
摘要： The invention relates to a new class of compounds which are inhibitors of IMPDH enzyme activity. The have the formula where A, D and B have the meanings listed in the description. The invention also relates to pharmaceutical compositions containing these compounds and to methods for IMPDH activity inhibition by using them.

20. 发明专利

ES2222336T3 INHIBIDORES DE GIRASAS Y SUS USOS. 未知
公开(公告)号：ES2222336T3
公开(公告)日：2005-02-01
申请号：ES01903077
申请日：2001-01-16
申请人： VERTEX PHARMA
发明人： CHARIFSON PAUL , STAMOS DEAN , BADIA MICHAEL , GRILLOT ANNE-LAURE , RONKIN STEVEN , TRUDEAU MARTIN
IPC分类号： C07D231/38 , A61K31/4155 , A61K31/421 , A61K31/422 , A61K31/427 , A61K31/454 , A61K31/5377 , A61P1/00 , A61P11/00 , A61P13/02 , A61P13/08 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/08 , A61P25/00 , A61P31/04 , A61P31/06 , A61P43/00 , C07D403/04 , C07D413/04 , C07D417/04 , C07D417/14
摘要： El uso de un compuesto que tiene la fórmula: o de una de sus sales farmacéuticamente aceptables, fórmula en la que R1 es un grupo opcionalmente sustituido, seleccionado entre un grupo alifático(C1-C6), - C(R4)2(CH2)nNRCOR, -C(R4)=N-OR, -C(R4)=N-OC(=O)(grupo alifático(C1-C6)), -C(R4)=NNRCO2(grupo alifático(C1-C6)), -C(R4)=NNRCOR, -C(R4)=NN(R)2, -C(R4)2(CH2)nNRCO2(grupo alifático(C1-C6)), -CO2(grupo alifático(C1-C6)), -CON(R)2, - C(R4)2(CH2)nCON(R)2, -C(R4)2(CH2)nSO2N(R)2, -CONH-OR, - SO2N(R)2, o -C(R4)2(CH2)nNRSO2(grupo alifático C1-C6)); n es cero o uno; cada R se selecciona independientemente entre hidrógeno o un grupo alifático(C1-C6) opcionalmente sustituido; R2 se selecciona entre hidrógeno o, cuando R1 es -CO2(grupo alifático(C1-C3)) o -CONH(grupo alifático(C1- C3)), R2 se selecciona además entre -halo, -CN, -grupo alifático(C1-C4), un heterociclilo de tres a cinco miembros, o un heteroarilo de cinco miembros; el Anillo A es un anillo de heteroarilo seleccionado entre tiazol, oxazol, imidazol o pirazol, en el que dicho imidazol está opcionalmente unido por medio de un puente(C1-C3) desde un nitrógeno del anillo de imidazol a un Ar para formar un anillo fusionado de cinco a siete miembros; Z es C-R3 o N-R3; R3 es -(CH2)pN(R5)2 o un grupo opcionalmente sustituido, seleccionado entre un grupo alifático(C1-C8), heterociclilo, heterociclilalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo; cada R4 se selecciona independientemente entre hidrógeno, un grupo alifático(C1-C6) opcionalmente sustituido, o dos R4, considerados junto con el carbono al que están unidos, forman un anillo alifático de tres a seis miembros; cada R5 se selecciona independientemente entre hidrógeno, un grupo alifático(C1-C4) opcionalmente sustituido, o dos R5, considerados junto con el nitrógeno al que están unidos, forman un anillo heterocíclico de cinco o seis miembros; p es un número entero de cero a cuatro cuando Z es C-R3, o un número entero de uno a cuatro cuando Z es N- R3; y Ar es unanillo de arilo, heteroarilo o heterociclilo, opcionalmente sustituido, para la preparación de una composición farmacéutica para tratar una infección bacteriana en un mamífero.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式